Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
$3.78
+0.1%
$5.89
$2.62
$8.99
$38.67M0.6714,708 shs3,529 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.28
-2.4%
$0.49
$0.25
$1.28
$14.83M1.19132,331 shs525,402 shs
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$0.17
-0.6%
$0.19
$0.14
$0.84
$61.05M0.96987,117 shs941,223 shs
Exagen Inc. stock logo
XGN
Exagen
$4.08
+1.2%
$3.90
$1.30
$6.22
$73.02M1.4684,914 shs99,401 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
0.00%-14.49%-27.89%-45.18%-45.56%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%-31.79%-36.64%-59.20%-76.67%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
0.00%-0.87%-7.62%-29.34%-78.81%
Exagen Inc. stock logo
XGN
Exagen
0.00%+4.95%+24.77%+18.88%+168.67%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
1.9417 of 5 stars
3.03.00.00.02.00.81.3
Exagen Inc. stock logo
XGN
Exagen
4.4854 of 5 stars
3.55.00.04.52.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
2.00
Hold$0.2547.06% Upside
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$7.5083.82% Upside

Current Analyst Ratings Breakdown

Latest ENZ, XGN, PIII, and BNR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2025
Exagen Inc. stock logo
XGN
Exagen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/13/2025
Exagen Inc. stock logo
XGN
Exagen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00 ➝ $8.00
(Data available from 4/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
$515.82M0.07N/AN/A$10.56 per share0.36
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.51N/AN/A$1.09 per share0.26
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$1.50B0.04$0.07 per share2.32$0.45 per share0.38
Exagen Inc. stock logo
XGN
Exagen
$55.64M1.31N/AN/A$1.33 per share3.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
-$92.07M-$1.88N/AN/A-83.50%-60.68%-42.30%N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%6/11/2025 (Estimated)
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$57.77M-$0.98N/AN/AN/A-6.95%-71.31%-11.93%5/6/2025 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$0.83N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)

Latest ENZ, XGN, PIII, and BNR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2025Q4 2024
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$0.17-$0.32-$0.15-$0.36$378.88 million$370.69 million
3/25/2025Q4 2024
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
-$1.3970-$1.08+$0.3170-$1.08N/A$17.27 million
3/17/2025Q2 2025
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A-$0.02N/A-$0.03N/A$7.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40141.34%N/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/A
3.04
2.78
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
1.11
0.53
0.53
Exagen Inc. stock logo
XGN
Exagen
1.54
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
30.03%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
7.75%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
30.30%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
15.76%
Exagen Inc. stock logo
XGN
Exagen
26.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
1,39010.24 million7.14 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
500359.12 million294.74 millionNot Optionable
Exagen Inc. stock logo
XGN
Exagen
22017.90 million13.03 millionOptionable

Recent News About These Companies

Exagen Inc. (NASDAQ:XGN) Short Interest Down 23.5% in March
Exagen Full Year 2024 Earnings: EPS Beats Expectations
Exagen (XGN) Gets a Buy from Canaccord Genuity
Exagen reports Q4 EPS (20c), consensus (24c)
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$3.78 +0.01 (+0.13%)
Closing price 03:57 PM Eastern
Extended Trading
$3.85 +0.08 (+1.99%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.28 -0.01 (-2.41%)
Closing price 03:58 PM Eastern
Extended Trading
$0.29 +0.01 (+2.47%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

P3 Health Partners stock logo

P3 Health Partners NASDAQ:PIII

$0.17 0.00 (-0.58%)
Closing price 03:59 PM Eastern
Extended Trading
$0.16 -0.01 (-5.88%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

Exagen stock logo

Exagen NASDAQ:XGN

$4.08 +0.05 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.05 -0.03 (-0.74%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.